中成药联合奥司他韦治疗儿童流感的疗效与安全性:一项Meta分析
该Meta分析纳入21项RCT共2960例流感患儿,比较中成药联合奥司他韦与单用奥司他韦的疗效与安全性。结果显示联合治疗可缩短发热、咳嗽、鼻塞、咽痛持续时间及病毒排毒时间,并减少不良反应发生,但研究间异质性和发表偏倚明显,结论需谨慎看待。
要点
- 中成药联合奥司他韦可缩短流感患儿发热、咳嗽、鼻塞、咽痛持续时间。
- 联合治疗可缩短病毒排毒时间并减少不良反应发生。
- 因异质性和发表偏倚明显,结果需谨慎解读。
核心结论
- 中成药联合奥司他韦可缩短流感患儿症状持续时间、病毒排毒时间并减少不良反应发生。
- 因研究数据存在明显异质性和发表偏倚,上述结果需谨慎看待。
研究设计与样本
- Meta分析检索CNKI、万方、SinoMed、PubMed、Cochrane library和Embase自建库至2020年12月12日的RCT。
- 共纳入21项RCT,涉及2960例流感患儿。
主要发现
- 与单用奥司他韦相比,联合治疗缩短发热持续时间(MD=-0.64,95%CI:-0.86至-0.41,P<0.00001)。
- 联合治疗缩短咳嗽持续时间(MD=-0.82,95%CI:-1.02至-0.62,P<0.00001)。
- 联合治疗缩短鼻塞持续时间(MD=-0.88,95%CI:-1.15至-0.61,P<0.00001)。
- 联合治疗缩短咽痛持续时间(MD=-0.92,95%CI:-1.26至-0.57,P<0.00001)。
- 联合治疗缩短病毒排毒时间(MD=-0.53,95%CI:-0.70至-0.36,P<0.00001)并减少不良反应发生(RR=0.53,95%CI:0.34至0.83,P=0.005)。
临床怎么用
- 在儿童流感治疗中可考虑中成药联合奥司他韦以缩短症状持续时间和病毒排毒时间。
- 联合用药时需关注中成药的不良反应风险,并个体化评估获益与风险。
局限性
- 纳入研究存在明显异质性。
- 研究数据存在发表偏倚。
- 需设计更严格的RCT验证中成药在流感患儿中的疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Recently, Chinese patent medicines (CPMs) have been widely used to treat children with influenza in China, with curative effects. Therefore, the efficacy and safety of such treatment require further evaluation. The present meta-analysis integrated data from several independent studies to determine overall treatment trends in children with influenza. Methods: The following databases were searched for randomized controlled trials (RCTs) published from their inception to December 12, 2020: CNKI, Wanfang, SinoMed, PubMed, Cochrane library, and Embase. Two researchers independently extracted the data, assessed the methodological quality of the studies, and conducted a meta-analysis of the results using Review Manager 5.2. The results were assessed using forest plots, and publication bias was evaluated using a funnel plot. Results: A total of 21 RCTs involving 2960 cases were included. Compared to oseltamivir alone, CPMs combined with oseltamivir reduced the duration of symptoms, including that of fever (mean difference [MD] = -0.64, 95% confidence interval [CI]: -0.86 to -0.41, P < 0.00001), cough (MD = -0.82, 95% CI: -1.02 to -0.62, P < 0.00001), nasal obstruction (MD = -0.88, 95% CI: -1.15 to -0.61, P < 0.00001), and sore throat (MD = -0.92, 95% CI: -1.26 to -0.57, P < 0.00001). Combined therapy also reduced the time of viral shedding (MD = -0.53, 95% CI: -0.70 to -0.36, P < 0.00001) and the occurrence of adverse drug reactions (ADRs) (RR=0.53, 95% CI: 0.34 to 0.83, P = 0.005). Conclusions: CPMs combined with oseltamivir reduced the duration of symptoms, shortened the time of viral shedding, and reduced the number of ADRs. However, these results should be considered with caution because there was marked heterogeneity and publication bias in the research data. More rigorous RCTs should be designed to verify the effect of CPMs in children with influenza.
引用
- Duan NF, Liu B, Li XN, et al. Efficacy and Safety of Chinese Patent Medicine Combined With Oseltamivir in Treatment of Children With Influenza: A meta-Analysis. Front Pharmacol. 2021. PMID: 34421591. doi:10.3389/fphar.2021.682732
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。